A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

NCT07134088 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab

Sponsor

Amgen

Collaborators

[object Object]